| 词条 | Veloxis Pharmaceuticals |
| 释义 |
| name = Veloxis Pharmaceuticals A/S | logo = Veloxis_Pharmaceuticals_logo.svg | type = Aktieselskab | traded_as = {{OMX|CSE36992|VELO}} | industry = Pharmaceuticals | location = Hørsholm, Denmark | num_employees = 51 | key_people = Craig Collard (CEO), Michael Heffernan (Chairman) | products = Orally-delivered pharmaceuticals | homepage = www.veloxis.com }}Veloxis Pharmaceuticals A/S, formerly LifeCycle Pharma A/S, develops improved versions of difficult-to-formulate drugs with its proprietary drug formulation technology, called MeltDose®. Veloxis is focused on building a clinical and market-stage pharmaceutical business around its late-stage transplant immunosuppression product candidate LCP-Tacro. The company was founded in 2002 as a spin-off from H. Lundbeck A/S. Veloxis is headquartered in Horsholm, Denmark, with an office in Cary, North Carolina [1] MeltDose Technology PlatformMeltDose works by incorporating a drug substance with low water solubility into a "meltable" vehicle.[2] It is then sprayed on an inert particulate carrier using fluid bed equipment. The melt is solidified when deposed on a particle carrier, and thus captures the active drug in a solid dispersion either as a solid solution or in a nano-crystalline state. The particle size is then increased by controlling and optimizing the product temperature and feed rate of the melt. The granulate can be directly compressed into tablets without additional processing steps besides blending with a lubricant. In addition, the technology allows for customization of the release profile. Once in tablet form, the dissolution profile and the particle size of drugs manufactured using MeltDose® technology remain stable allowing for a long shelf-life. Product Pipeline[3]
References1. ^{{Cite web | url=http://www.veloxis.com | title=Home - Veloxis - Transplant Patients}} 2. ^Van Arnum P. Formulation Development Forum: Controlled Agglomeration for Poorly Soluble Drugs. Pharmaceutical Technology 35(7). 3. ^{{Cite web | url=http://www.veloxis.com | title=Home - Veloxis - Transplant Patients}} 4. ^Clinicaltrials.gov identifier: NCT01187953 5. ^Langone A, Steinberg SM, Gedaly R, et al. Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO (STRATO): an open-label, multicenter, prospective phase 3b study. Clin Transplant. 2015;29(9):796-805. https://onlinelibrary.wiley.com/doi/full/10.1111/ctr.12581 6. ^{{Cite web | url=http://www.santarus.com | title=Home | Salix Pharmaceuticals}} External links
4 : Pharmaceutical companies of Denmark|Life science companies based in Copenhagen|Companies based in Hørsholm Municipality|Companies established in 1999 |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。